Bristol-Myers Sees Five Meds Cushioning The Fall Off The Patent Cliff

Just two days after being named the next chief executive officer at Bristol-Myers Squibb, Lamberto Andreotti told a crowd of Wall Street analysts that the drug maker is on track to launch five medicines by 2012 - the year two key drugs go off patent - and vowed that strong financial growth will resume by 2014